Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Diversified Dividend Stocks to Buy Right Now. On March 30, Reuters reported that Royalty Pharma entered into a $500 million research and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
ST. PETER PORT, Guernsey & TORONTO–(BUSINESS WIRE)–Duke Royalty Limited (“Duke Royalty”), a public diversified royalty company (AIM:DUKE), and Oliver Wyman, a management consultancy wholly owned by ...
Royalty Pharma has inked a $500 million research-and-development co-funding agreement with Johnson & Johnson to support development of a proposed drug for autoimmune diseases. Royalty Pharma, a New ...
Portfolio & Royalty Receipts rose 10–13% to $925m/$887m, reinforcing 2030 target upside and buyback tailwinds. See more on ...
SYLVESTER, Ga. (WALB) – One year after a tragic crash on I-75 nearly claimed her life, 23-month-old Royalty is showing the world what resilience truly looks like. One year ago today, Royalty Johnson ...
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by ...
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised full year 2026 guidance: Portfolio Receipts expected to ...
On March 30, Reuters reported that Royalty Pharma entered into a $500 million research and development agreement with Johnson & Johnson (NYSE:JNJ) to support an experimental antibody treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results